Demonstration and characterization of specific binding sites for Factor VIII/von Willebrand factor on human platelets

123Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The presence of specific Factor VIII/ von Willebrand factor (FVIII/vWF) binding sites on human platelets has been demonstrated by using 125I-FVIII/vWF and washed human platelets. Binding is ristocetin-dependent and increases in proportion to the concentration of ristocetin from 0.2 to 1 mg/ml. Binding of 125I-FVIII/vWF to platelets can be competitively inhibited by unlabeled human or bovine FVIII/vWF, but not by human thrombin, fibrinogen, α2-macroglobulin, equine collagen, or a lectin of Ricinus communis. Scatchard analysis of binding data indicated that the dissociation constant of FVIII/vWF receptors is 0.45-0.5 nM. There are 31,000 binding sites per platelet at 1 mg/ml of ristocetin concentration. The optimal pH range for binding is from 7.0 to 7.5. At a concentration of 2 mM, EGTA inhibits 86% of the binding; however, 20 mM of Ca++, Mg++, or EDTA have little effect. Binding sites for FVIII/vWF were found only on platelets, and no significant binding was detected with human erythrocytes or polymorphonuclear leukocytes.

Cite

CITATION STYLE

APA

Kao, K. J., Pizzo, S. V., & McKee, P. A. (1979). Demonstration and characterization of specific binding sites for Factor VIII/von Willebrand factor on human platelets. Journal of Clinical Investigation, 63(4), 656–664. https://doi.org/10.1172/JCI109348

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free